Key result
Immune checkpoint inhibitors linked to higher MACE in cancer patients versus non-exposed controls.
Why the study?
The true incidence of major adverse cardiovascular events other than myocarditis after ICI treatment remains unknown because late-occurring side effects are rarely reported in prospective trials.
Does immune checkpoint inhibitor treatment increase the incidence of MACE in cancer patients compared to non-ICI treated cancer patients and population controls?
Population
672 patients treated with ICIs
Comparison
ICI-treated cancer patients vs cancer patients not treated with ICIs and population controls
Design
Matched cohort study
Authors
Loading...
MACE incidence appears elevated after ICI exposure in real-world data; supports targeted surveillance in those with prior HF but leaves causal risk open.
Cohort (n=672)
Does immune checkpoint inhibitor treatment increase the incidence of MACE in cancer patients compared to non-ICI treated cancer patients and population controls?
p-value: p=0.041
Immune checkpoint inhibitors are associated with a significantly higher incidence of major adverse cardiovascular events, particularly heart failure, compared to matched cancer and population controls.
Laenens et al. (2022) conducted a cohort in Cancer (n=672). Immune checkpoint inhibitors (ICIs) vs. Cancer patients not treated with ICIs and population controls was evaluated on MACE (composite of acute coronary syndrome, heart failure, stroke, and transient ischemic attack) (p=0.041). Immune checkpoint inhibitor treatment in cancer patients was associated with a significantly higher cumulative incidence of MACE compared to non-exposed controls (P=0.041).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: